Acadia Pharmaceuticals (ACAD) Common Equity (2010 - 2026)

Acadia Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 63.1% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 63.1% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 67.49% from the prior year.
• Common Equity improved to $1.2 billion in Q1 2026 per ACAD's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.2 billion in Q1 2026 and bottomed at $362.2 million in Q3 2023.
• The 5-year median for Common Equity is $464.0 million (2024), against an average of $620.0 million.
• Across the five-year window, Common Equity dropped 25.97% in 2022 and surged 69.72% in 2024, its largest moves.
• Year by year, Common Equity stood at $400.4 million in 2022, then rose by 7.83% to $431.8 million in 2023, then jumped by 69.72% to $732.8 million in 2024, then soared by 67.49% to $1.2 billion in 2025, then rose by 1.68% to $1.2 billion in 2026.
• Per Business Quant, the three latest ACAD Common Equity figures stand at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $917.3 million (Q3 2025).